Form 4: Lilly Endowment Sells $3.15M in Eli Lilly Stock

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported the sale of 3,658 shares of common stock for approximately $3.15 million under a Rule 10b5-1 plan.

Summary

• Lilly Endowment Inc., a significant shareholder and 10% owner of Eli Lilly & Co. (LLY), reported the sale of common stock.
• A total of 3,658 shares were sold in two separate transactions on October 10, 2025.
• The first transaction involved the sale of 468 shares at a weighted average price of $862.34 per share, with prices ranging from $862.00 to $862.74.
• The second transaction involved the sale of 3,190 shares at a weighted average price of $863.369 per share, with prices ranging from $863.00 to $863.995.
• The total value of the shares sold is approximately $3,157,600.
• Following these transactions, Lilly Endowment Inc. beneficially owns 94,533,320 shares of Eli Lilly & Co. common stock.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was pre-planned under a 10b5-1 plan, which typically indicates a routine portfolio management decision rather than a negative outlook on the company's prospects. The remaining ownership is still very substantial.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned sales and transparency in insider trading.
• Lilly Endowment Inc. remains a substantial shareholder, holding over 94.5 million shares, demonstrating continued significant investment in Eli Lilly & Co.

Negatives

• The sale represents a reduction in direct beneficial ownership by a significant insider, which can sometimes be perceived negatively by the market, even if pre-planned.

Risks

• While the sale is pre-planned, a large insider sale could potentially lead to minor negative market sentiment or speculation if not fully understood by investors.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Eli Lilly & Co.'s future performance or strategic direction. It solely reports an insider transaction.

Industry Context

This Form 4 filing reports a routine insider transaction by a significant shareholder and does not directly relate to broader industry trends or competitive landscape. Such pre-planned sales are common for large institutional holders managing their portfolios.

Comparison to Industry Standards

• The sale of shares by a 10% owner under a Rule 10b5-1 plan is a standard practice for large institutional investors to manage their holdings in a compliant and transparent manner.
• The volume of shares sold, while significant in absolute terms, represents a very small fraction of Lilly Endowment Inc.'s total holdings in Eli Lilly & Co., which is typical for portfolio rebalancing rather than a change in investment thesis.

Related Party Transactions

• The sale of common stock by Lilly Endowment Inc., a 10% owner and entity with a director relationship to Eli Lilly & Co., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction provides transparency regarding a significant shareholder's activity. The sale is minor relative to total shares outstanding and the Endowment's remaining holdings, so direct impact on share price is likely minimal.
• Regulatory Bodies: The filing ensures compliance with Section 16(a) of the Securities Exchange Act of 1934, providing required disclosure to the SEC.

Key Dates

Recommendation

The reported transaction is a pre-planned sale by a significant institutional shareholder under a Rule 10b5-1 plan. This is a routine event for portfolio management and does not typically signal a change in the fundamental outlook for Eli Lilly & Co. Given the nature of the transaction, it is unlikely to have a significant impact on the company's valuation or future prospects, thus a 'hold' recommendation is appropriate.

Keywords

Eli Lilly, LLY, Lilly Endowment Inc., Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Beneficial Ownership